Covishield produced more antibodies than Covaxin: Study

The Covishield vaccine developed by Oxford/AstraZeneca has produced more antibodies than the Bharat Biotech’s Covaxin, according to an experimental study by Coronavirus Vaccine-induced Antibody Titre (COVAT), including healthcare workers (HCW) who have been administered both doses of either of the two vaccines.

Compared to Covaxin after the first dose, seropositivity rates to anti-spike antibodies were significantly higher in Covishield recipients, the study asserted.

The study is a preprint and has not been expert-reviewed; hence it should not be used as a guide to clinical practice. It claimed that both vaccines, Covishield and Covaxin, obtained a good response after two doses, but seropositivity and median anti-spike antibodies were notably higher in Covishield.

The study said among the 552 healthcare workers (HCW), 325 male and 227 female; 456 and 96 received the first jab of Covishield and Covaxin, respectively. Primarly, 79.3 percent reported seropositivity after the first dose. The responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield compared to Covaxin recipients.

The study included healthcare workers who have received either of the two vaccines, Covishield and Covaxin, with or without a history of SARS-CoV-2 infection in the past.

“This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without a past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four-time points between 21 days or more after the first dose to 6 months after the second dose,” the study said.

The conclusion of the study, however claimed that both vaccines have obtained good immunity responses. While both vaccines received an immune response, seropositivity rates to anti-spike antibodies were significantly higher in Covishield recipients than in Covaxin after the first dose. The ongoing COVAT study will further brief the immune response between two vaccines after the second dose.

(Inputs from ANI)

Latest Indian news

Popular Stories

Latest Video